A critical review of cyclosporine therapy in inflammatory bowel disease

Sandborn, William J.

doi:10.1002/ibd.3780010107

Cited by 122 publications

(82 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Corticosteroids and salicylates may ordinarily be used during pregnancy. However, cyclosporine should be avoided if possible, since experience with this drug in pregnant women with UC, though limited to a few cases, suggests an apparent high incidence of prematurity and low birth weight [1]. Leukocytapheresis has recently been used to induce remission in UC patients who failed to respond to corticosteroids [2,3,4,5,6,7,8].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Efficacy of Leukocytapheresis in a Pregnant Woman with Severe Active Ulcerative Colitis

et al. 2006

View full text Add to dashboard Cite

Leukocytapheresis has recently been used to induce remission in patients with ulcerative colitis (UC) who fail to respond to corticosteroids. We could not find a report in the literature on leukocytapheresis for UC with gestational exacerbation. We have recently encountered this unique condition and report the details here. A 30-year-old Japanese woman with left-sided severe UC was corticosteroid-dependent and had recurrence of the active disease during tapering of corticosteroid. She declined any dose increase and the use of any immunosuppressive agent because she was in the 13th week of pregnancy. Then, concomitant leukocytapheresis was performed without increasing the corticosteroid dose. Recovery was rapid and dramatic. Mucous and bloody stool decreased after the first session, and she had remission 2 weeks later. She underwent a total of four sessions without complications. After 6 weeks, she was discharged from our hospital and underwent maintenance treatment as an outpatient with mesalazine and corticosteroid tapering. Subsequently, she gave birth to a healthy baby girl by an uncomplicated vaginal delivery while keeping the remitted stage of UC.

show abstract

Section: Introductionmentioning

confidence: 99%

Therapeutic Efficacy of Leukocytapheresis in a Pregnant Woman with Severe Active Ulcerative Colitis

et al. 2006

View full text Add to dashboard Cite

show abstract

“…CsA also indirectly inhibits the function of B-cells by suppression of T-helper cells. CsA has a more rapid onset of clinical action than either 6-MP or AZA, which can require 3-6 mo before showing detectable disease suppressing activity [121] . Patients with CD who respond to CsA show rapid improvements within 2-3 wk [121] .…”

Section: Cyclosporine A/tacrolimusmentioning

confidence: 99%

“…CsA has a more rapid onset of clinical action than either 6-MP or AZA, which can require 3-6 mo before showing detectable disease suppressing activity [121] . Patients with CD who respond to CsA show rapid improvements within 2-3 wk [121] . Clinical improvements have also been seen within 1-2 wk following the initiation of therapy with CsA in severe UC [121] .…”

Section: Cyclosporine A/tacrolimusmentioning

confidence: 99%

“…Patients with CD who respond to CsA show rapid improvements within 2-3 wk [121] . Clinical improvements have also been seen within 1-2 wk following the initiation of therapy with CsA in severe UC [121] . Tacrolimus, a macrolide antibiotic, has immunomodulator properties like CsA but two orders of magnitude more potent than CsA.…”

Section: Cyclosporine A/tacrolimusmentioning

confidence: 99%

See 1 more Smart Citation

Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management

Hosseini‐Carroll¹,

Mutyala²,

Seth³

et al. 2015

WJGPT

View full text Add to dashboard Cite

Manas K made critical revisions of the manuscript; Becker F and Alexander JS contributed equally as senior authors. Conflict-of-interest statement:There are no known conflicts of interest. The authors (Pegah Hosseini-Carroll, Monica Mutyala, Abhishek Seth, Shaheen Nageeb, Demiana Soliman, Moheb Boktor, Ankur Sheth, Jonathon Chapman, James Morris, Paul Jordan, Kenneth Manas, Felix Becker, and J Steven Alexander) have no relevant financial considerations related to this proposal, and the study was not supported by any corporate entity. There is no known intellectual property associated with this report. AbstractInflammatory bowel diseases (IBD) are chronic idiopathic inflammatory conditions characterized by relapsing and remitting episodes of inflammation which can affect several different regions of the gastrointestinal tract, but also shows extra-intestinal manifestations. IBD is most frequently diagnosed during peak female reproductive years, with 25% of women with IBD conceiving after their diagnosis. While IBD therapy has improved dramatically with enhanced surveillance and more abundant and powerful treatment options, IBD disease can have important effects on pregnancy and presents several challenges for maintaining optimal outcomes for mothers with IBD and the developing fetus/neonate. Women with IBD, the medical team treating them (both gastroenterologists and obstetricians/gynecologists) must often make highly complicated choices regarding conception, pregnancy, and post-natal care (particularly breastfeeding) related to their choice of treatment options at different phases of pregnancy as well as post-partum. This current review discusses current concerns and recommendations for pregnancy during 157November 6, 2015|Volume 6|Issue 4| WJGPT|www.wjgnet.com Hosseini-Carroll P et al . Pregnancy and inflammatory bowel diseases IBD and is intended for gastroenterologists, general practitioners and IBD patients intending to become, (or already) pregnant, and their families. We have addressed patterns of IBD inheritance, effects of IBD on fertility and conception (in both men and women), the effects of IBD disease activity on maintenance of pregnancy and outcomes, risks of diagnostic procedures during pregnancy and potential risks and complications associated with different classes of IBD therapeutics. We also have evaluated the clinical experience using "top-down" care with biologics, which is currently the standard care at our institution. Post-partum care and breastfeeding recommendations are also addressed. Core tip: Inflammatory bowel diseases (IBD) are chronic inflammatory conditions characterized by relapsing and remitting episodes of intestinal inflammation. IBD is most frequently diagnosed during peak female reproductive years, with 25% of women with IBD conceiving after their diagnosis. While therapies have improved dramatically, IBDs have important effects on pregnancy and present challenges for maintaining optimal outcomes for mothers and their developing fetus/ neonate. Women with IBD and physician...

show abstract

“…It has been proposed as a rapid-acting alternative or adjunct to azathioprine or 6-mercaptopurine therapy in IBD [33]. Numerous trials attempted to clarify its efficacy in CD and UC, using as guide the proven efficacy of CsA in other immune-related diseases such as psoriasis and rheumatoid arthritis [34].…”

Section: Cyclosporinementioning

confidence: 99%

Drug-Induced Nephrotoxicity in Inflammatory Bowel Disease

Oikonomou¹,

Kapsoritakis²,

Stefanidis³

et al. 2011

Nephron Clin Pract

View full text Add to dashboard Cite

Conservative management of inflammatory bowel disease (IBD) is based on a combination of drugs, including aminosalicylates (ASAs), steroids, antibiotics, immunosuppressives and biologic agents. Although various side effects have been related to treatment regimens, drug-induced nephrotoxicity is rather uncommon. Furthermore, it is often underestimated since renal function deterioration may be attributed to the underlying disease. The nephrotoxicity of ASAs and cyclosporine A seems well established, but recent data have suggested a possible role of biologic agents such as infliximab and adalimubab in renal impairment. The aim of this review is to summarize the nephrotoxic effects of medical treatment as well as to express possible caveats in the administration of novel agents in IBD.

show abstract

A critical review of cyclosporine therapy in inflammatory bowel disease

Cited by 122 publications

References 105 publications

Therapeutic Efficacy of Leukocytapheresis in a Pregnant Woman with Severe Active Ulcerative Colitis

Therapeutic Efficacy of Leukocytapheresis in a Pregnant Woman with Severe Active Ulcerative Colitis

Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management

Drug-Induced Nephrotoxicity in Inflammatory Bowel Disease

Contact Info

Product

Resources

About